Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drop linked to potential violations of federal securities laws [1][3]. Group 1: Company Overview - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project, Project Matador, is designed to provide dedicated power for AI workloads [4]. Group 2: IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Group 3: Stock Price Impact - On December 12, 2025, Fermi's stock dropped by $5.16 per share, over 33%, following the termination of the Advance in Aid of Construction Agreement by the First Tenant [7]. - The stock price fell from $15.25 per share on December 11, 2025, to $10.09 per share on December 12, 2025 [7].

Core Viewpoint - A class action lawsuit has been initiated against BlackRock TCP Capital Corp. for alleged securities fraud, with a focus on misleading statements and undisclosed adverse facts regarding the company's business and operations during the specified Class Period from November 6, 2024, to January 23, 2026 [1]. Group 1: Lawsuit Details - The lawsuit claims that BlackRock TCP's investments were not being valued appropriately, leading to understated unrealized losses and overstated net asset value (NAV) [1]. - Defendants allegedly failed to disclose that portfolio restructuring efforts were ineffective in resolving credit challenges or improving portfolio quality [1]. - The misleading statements made by the defendants about BlackRock TCP's business and prospects resulted in investor damages when the true details became public [1]. Group 2: Legal Process and Participation - Investors who purchased BlackRock TCP securities during the Class Period may be entitled to compensation without upfront costs through a contingency fee arrangement [1]. - To participate in the class action, investors must act by April 6, 2026, to serve as lead plaintiff or can choose to remain absent and still be eligible for any potential recovery [1]. - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions and has recovered significant amounts for investors in the past [1].

Core Viewpoint - A class action lawsuit has been initiated against REGENXBIO, Inc. for alleged securities fraud during the period from February 9, 2022, to January 27, 2026, with investors potentially entitled to compensation without upfront costs [1] Group 1: Lawsuit Details - The lawsuit claims that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I, also known as Hurler syndrome [1] - Defendants allegedly made positive assertions about RGX-111's trial success based on favorable biomarker and safety data while concealing adverse facts about the trial's efficacy and safety [1] - Investors reportedly suffered damages when the true details about the trial were revealed [1] Group 2: Legal Representation - Investors wishing to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [1] - The Rosen Law Firm, known for its success in securities class actions, encourages investors to select qualified counsel with a proven track record [1] - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 [1]

Core Viewpoint - Investors in REGENXBIO Inc. have the opportunity to lead a securities fraud lawsuit against the company due to alleged misleading statements regarding the efficacy and safety of its product candidate RGX-111 [1] Group 1: Lawsuit Details - The Schall Law Firm is reminding investors of a class action lawsuit against REGENXBIO Inc. for violations of the Securities Exchange Act of 1934 [1] - The class period for the lawsuit is defined as between February 9, 2022, and January 27, 2026 [1] - Investors who suffered losses during this period are encouraged to contact the Schall Law Firm before April 14, 2026 [1] Group 2: Allegations Against the Company - The complaint alleges that REGENXBIO made false and misleading statements about RGX-111 while concealing negative data regarding its efficacy and safety [1] - A significant issue arose when an intraventricular CNS tumor was discovered in a participant treated in the RGX-111 study, which contradicted the company's positive statements [1] - The lawsuit claims that the company's public statements were materially misleading throughout the class period, leading to investor damages when the truth was revealed [1]

Core Viewpoint - Hagens Berman is notifying investors about a pending securities class action against F5, Inc. due to allegations of misleading statements regarding the security of its BIG-IP products, which resulted in significant financial losses for investors [1][2]. Group 1: Allegations and Impact - The lawsuit claims that F5 executives misled the market about the security of its core products, particularly after a sophisticated nation-state threat actor allegedly accessed F5's systems and exfiltrated sensitive source code [2][4]. - Following the revelation of the security breach in October 2025, F5's market value dropped by over $2 billion due to a significant decline in stock price [2]. - The breach was disclosed on October 15, 2025, revealing that a nation-state actor had maintained long-term access to F5's systems, which included the BIG-IP product development environment [7]. Group 2: Financial Performance and Guidance - F5's disappointing 4Q FY25 results, released on October 27, 2025, indicated a significant reduction in expected sales and renewals, elongated sales cycles, and increased expenses due to ongoing remediation efforts [7]. - The stock price fell by $22.83, or 7%, the day after the poor performance announcement, which was compounded by several analyst downgrades [7]. - The class period for the lawsuit is defined as October 28, 2024, to October 27, 2025, with a lead plaintiff deadline set for February 17, 2026 [5].

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its drug candidate AMT-130 and its regulatory prospects with the FDA [1][11]. Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, including Huntington's disease (HD) [3]. - The company's leading drug candidate, AMT-130, aims to slow the progression of HD, a fatal inherited disorder with no existing cure [4]. Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130, known as the Pivotal Study, in March 2022 [4]. - The FDA had previously agreed that the Pivotal Study would not include a placebo comparator, allowing results to be compared to an external historical dataset, ENROLL-HD, for potential BLA submission [5]. Investor Communication and Stock Performance - On September 24, 2025, uniQure announced topline results from the Pivotal Study, leading to a significant increase in share price from $13.66 to $47.50, a nearly 250% rise [7][8]. - By October 29, 2025, shares were trading above $70.00, and the company raised approximately $345 million through a public offering shortly after the positive study results [9]. Allegations of Misrepresentation - The lawsuit alleges that uniQure misrepresented the FDA's approval of the Pivotal Study design and downplayed the likelihood of delays in the BLA timeline, leading to inflated stock prices based on misleading information [11]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the study data was adequate for BLA submission, resulting in a stock price drop of over 49% [10]. Legal Process for Investors - Investors who acquired uniQure shares during the class period may seek to be appointed as lead plaintiffs by April 13, 2026, to represent the class in the lawsuit [2][12].

Core Viewpoint - The SLM Corporation, also known as Sallie Mae, is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with investors having until February 17, 2026, to seek lead plaintiff status [1]. Company Overview - SLM Corporation, through its subsidiaries, originates and services private education loans (PELs) [2]. Allegations of the Lawsuit - The lawsuit claims that during the class period, SLM made false or misleading statements and failed to disclose significant increases in early-stage delinquencies, leading to an overstatement of the effectiveness of its loss mitigation and loan modification programs [3]. - On August 14, 2025, TD Cowen reported a 49 basis points month-over-month increase in delinquencies for July 2025, which contradicted SLM's CFO's earlier assurances about delinquency rates following normal seasonal trends. Following this report, SLM's stock price fell by approximately 8% [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who invested in SLM securities during the class period to seek appointment as lead plaintiff, representing the interests of the class [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 and $8.4 billion over the past five years [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its drug, setrusumab, during the specified class period [2][3][5]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [2][5]. - The case is titled Bailey v. Ultragenyx Pharmaceutical Inc., et al, and is being heard in the United States District Court for the Northern District of California [2]. - Investors have until April 6, 2026, to file for lead plaintiff status [2][5]. Group 2: Allegations - The complaint alleges that Ultragenyx made false and misleading statements about the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients [3]. - It is claimed that Ultragenyx downplayed the risks associated with the Phase III Orbit study, which may not have achieved a statistically significant reduction in annualized fracture rate [3]. - The lawsuit asserts that the company's positive statements about its business and prospects were materially misleading and lacked a reasonable basis [3]. Group 3: Investor Actions - Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost [5][6]. - Investors can file to be lead plaintiff by the April 6, 2026 deadline or choose to remain absent from the class [6]. - The law firm offers a free case evaluation for investors who experienced losses related to Ultragenyx [6][7].

Core Viewpoint - A class action lawsuit has been filed against Kyndryl Holdings, Inc. and certain senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Kyndryl is a provider of enterprise technology services, offering advisory, implementation, and managed service capabilities to customers in over 60 countries. It is recognized as the world's largest IT infrastructure services provider [4]. Allegations and Financial Mismanagement - The lawsuit alleges that Kyndryl misrepresented its cash management practices, including the drivers of its adjusted free cash flow metric and the effectiveness of its internal controls over financial reporting for FY2025 and the first three quarters of FY2026 [5]. Stock Performance and Market Reaction - On February 9, 2026, Kyndryl announced a delay in releasing its fiscal Q3 2026 financial statement due to an accounting review of its cash management practices, which led to the immediate departures of its CFO and General Counsel. This announcement resulted in a stock price drop of $12.90 per share, or 55%, from $23.49 on February 8, 2026, to $10.59 on February 9, 2026 [6][7].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Plug Power provides hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets and develops infrastructure such as hydrogen production plants [4]. Legal Proceedings - Investors have until April 3, 2026, to request to lead the case in the U.S. District Court for the Northern District of New York, under the caption Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3]. Allegations - The lawsuit claims that Plug Power materially overstated the likelihood of receiving a $1.66 billion loan guarantee from the U.S. Department of Energy, which was intended to finance the construction of hydrogen production facilities [4]. Stock Performance - On October 7, 2025, Plug Power's stock dropped by $0.26 per share (6.3%) following the announcement of the abrupt departure of its CEO and President [5]. - On November 10, 2025, the stock fell by $0.09 per share (3.4%) after the company suspended activities under the DOE loan program [6]. - A further drop of $0.48 per share (17.6%) occurred on November 14, 2025, after reports confirmed the suspension of plans to construct hydrogen production facilities, jeopardizing the $1.66 billion DOE loan [7].